WASHINGTON, DC -- September 17, 2009 -- Patients with myelodysplastic syndromes (MDS) and anaemia may benefit from treatment with an erythropoietin (EPO)-based regimen plus supportive care without added complications as compared with those receiving supportive care alone, according to a study published in the September 17 issue of Blood.

The phase 3 prospective, randomised trial, conducted by research teams of the Eastern Cooperative Oncology Group, was designed to evaluate the efficacy and safety of EPO with or without granulocyte colony-stimulating factor (G-CSF) and supportive care (SC) with red blood cell transfusions for patients with early-stage MDS (n = 53), in comparison with supportive care alone (n = 57). More